Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study

被引：0
|
作者：
Sadayoshi Ito
Naoki Kashihara
Kenichi Shikata
Masaomi Nangaku
Takashi Wada
Yasuyuki Okuda
Tomoko Sawanobori
机构：
[1] Tohoku University School of Medicine,Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine
[2] Katta General Hospital,Center for Innovative Clinical Medicine
[3] Department of Nephrology and Hypertension,Division of Nephrology and Endocrinology, Graduate School of Medicine
[4] Kawasaki Medical School,Department of Nephrology and Laboratory Medicine
[5] Okayama University Hospital,Data Intelligence Department
[6] The University of Tokyo,Clinical Development Department
[7] Kanazawa University,undefined
[8] Daiichi Sankyo Co.,undefined
[9] Ltd.,undefined
[10] Daiichi Sankyo Co.,undefined
[11] Ltd.,undefined
来源：
Clinical and Experimental Nephrology | 2021年 / 25卷
关键词：
Esaxerenone; Macroalbuminuria; Phase III; Type 2 diabetes; Urinary albumin-to-creatinine ratio;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1070 / 1078
页数：8
相关论文
共 50 条
  • [21] A multicenter, open-label, single-arm, phase IV study evaluating the safety of biosimilar bevacizumab in patients with solid tumors
    Narayanan, P.
    Upveja, K. H.
    Deodhar, S.
    Kapur, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1613 - S1613
  • [22] Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
    Yap, Timothy A.
    Nakagawa, Kazuhiko
    Fujimoto, Nobukazu
    Kuribayashi, Kozo
    Guren, Tormod Kyrre
    Calabro, Luana
    Shapira-Frommer, Ronnie
    Gao, Bo
    Kao, Steven
    Matos, Ignacio
    Planchard, David
    Chatterjee, Arkendu
    Jin, Fan
    Norwood, Kevin
    Kindler, Hedy L.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (06): : 613 - 621
  • [23] A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1
    Hu, Xiaojie
    Wang, Jinhu
    Li, Wenbin
    Zeng, Kang
    Li, Yanling
    Tao, Juan
    Guan, Zhonghai
    Kang, Zhuang
    Xu, Zhongyuan
    Li, Changxing
    Ma, Yaohui
    Yang, Liu
    Wu, Zhuli
    Han, Pu
    Lin, Hongmei
    Li, Ben
    Hui, Ai-Min
    Wang, Xingli
    Lin, Xiaoxi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) Phase 3 Randomized Controlled Clinical Trial
    Ito, Sadayoshi
    Kashihara, Naoki
    Shikata, Kenichi
    Nangaku, Masaomi
    Wada, Takashi
    Okuda, Yasuyuki
    Sawanobori, Tomoko
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (12): : 1715 - 1727
  • [25] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Dang, Huibing
    Gao, Sujun
    Wang, Wei
    Zhou, Hu
    Chen, Yuqing
    Ma, Liangming
    Wang, Jishi
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Tong, Hongyan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1579 - 1587
  • [26] Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study
    Matsueda, Kei
    Fukudo, Shin
    Ogishima, Masayuki
    Naito, Yuki
    Nakamura, Soichiro
    BIOPSYCHOSOCIAL MEDICINE, 2024, 18 (01)
  • [27] Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study
    Kei Matsueda
    Shin Fukudo
    Masayuki Ogishima
    Yuki Naito
    Soichiro Nakamura
    BioPsychoSocial Medicine, 18
  • [28] Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
    Hiroaki Seino
    Diabetes Therapy, 2021, 12 : 863 - 877
  • [29] Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
    Leger, Jean-Marc
    De Bleecker, Jan L.
    Sommer, Claudia
    Robberecht, Wim
    Saarela, Mika
    Kamienowski, Jerzy
    Stelmasiak, Zbigniew
    Mielke, Orell
    Tackenberg, Bjoern
    Shebl, Amgad
    Bauhofer, Artur
    Zenker, Othmar
    Merkies, Ingemar S. J.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 (02) : 130 - 140
  • [30] Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
    Seino, Hiroaki
    DIABETES THERAPY, 2021, 12 (03) : 863 - 877
12345